Document is current
Any future updates will be listed below
-
Authors
Long, Georgina V
Tang, Hao
Desai, Keyur
Wang, Sheen
Del Vecchio, Michele
Larkin, James
Ritchings, Corey
Huang, Shu-Pang
Baden, Jonathan https://orcid.org/0000-0002-9423-8305
Balli, David
Chang, Han
Fusaro, Gina
Tenney, Daniel
Dolfi, Sonia https://orcid.org/0000-0001-9454-4583
Weber, Jeffrey https://orcid.org/0000-0002-4962-2957
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03068455 at ClinicalTrials.govnct03068455 at ClinicalTrials.govDocuments that mention this clinical trial
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
https://doi.org/10.1200/jco.22.00533
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
https://doi.org/10.1136/jitc-2025-012034
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
https://doi.org/10.1200/jco.21.02628
nct03068455 at ClinicalTrials.govDocuments that mention this clinical trial
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
https://doi.org/10.1200/jco.22.00533
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
https://doi.org/10.1136/jitc-2025-012034
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
https://doi.org/10.1200/jco.21.02628
Documents that mention this clinical trial
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
https://doi.org/10.1200/jco.22.00533
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
https://doi.org/10.1136/jitc-2025-012034
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
https://doi.org/10.1200/jco.21.02628
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb (N/A)
Link
- License Information
